Identification of extracellular matrix protein 1 as a potential plasma biomarker of ESCC by proteomic analysis using iTRAQ and 2D‐LC‐MS/MS

Wang, Xianghu; Peng, Yuan; Xie, Ming; Gao, Zhikui; Ye, Lihong; Pu, Yuepu; Liu, Ran

doi:10.1002/prca.201600163

Cited by 22 publications

(9 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, it is involved in various biological processes, such as cell proliferation, angiogenesis, migration and metastasis 11,12. ECM1 was found to promote metastatic progression and invasion in multiple cancer types, and overexpression of ECM1 has been incorporated into scoring models for indicating of poor clinical prognosis and metastatic potential in cancer patients 13,14. Compared with non-lymph node metastases, breast and lung tumors with lymph node metastases were more likely to be ECM1-positive 15.…”

Section: Introductionmentioning

confidence: 99%

<p>Extracellular matrix protein 1 (ECM1) is associated with carcinogenesis potential of human bladder cancer</p>

Wang

Zhou

et al. 2019

OTT

View full text Add to dashboard Cite

Background Bladder cancer (BCa) is a common urological malignant tumor worldwide, and recurrence and death still remain high. New therapeutic targets are needed to treat patients who are not sensitive to current therapy. Extracellular matrix protein 1 (ECM1) is a key player in multiple epithelial malignancies. However, the knowledge regarding the expression of ECM1 in BCa and the mechanisms by which ECM1 affects BCa tumor progression is unclear. Materials and methods ECM1 expression levels in BCa tissues and cells were detected by quantitative real-time PCR (qRT-PCR), immunohistochemistry and Western blot. ECM1 expression was suppressed by shRNAs. Cell Counting Kit-8 (CCK-8), luminescent cell viability assay and 5-ethynyl-2′-deoxyuridine (EdU) assay were used to detect cell proliferation. Flow cytometry and transwell assay were used to evaluate cell apoptosis and invasion, respectively. All statistical analyses were performed by using the GraphPad Prism 7 software package. Results In this study, the expression of ECM1 in BCa specimens and cell lines was examined and displayed a significant increase compared with noncancerous counterparts, while ECM1 -knockdown affected not only cell proliferation and migration, but also cell invasion ability and apoptosis potential, corresponding to the finding that ECM1 overexpression in BCa patients was associated with a poor prognosis. Additionally, after suppression of ECM1 , the expression of glucose transporter 1 ( GLUT1 ), lactate dehydrogenase ( LDHA ) and hypoxia-inducible factor 1α ( HIF-1α ), genes involved in Warburg effect regulation, were significantly decreased, and the lactate production was also obviously reduced in ECM1 -silenced cells. Conclusion Our investigations revealed that the expression of ECM1 was closely associated with tumor cell growth, migration and apoptosis at least in part through regulation of Warburg effect, defining ECM1 as an effective predictor in the carcinogenesis and postoperative recurrence of human BCa.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Extracellular matrix protein 1 (ECM1) is associated with carcinogenesis potential of human bladder cancer</p>

Wang

Zhou

et al. 2019

OTT

View full text Add to dashboard Cite

show abstract

“…In particular, high ECM1 level in serum of BC patients is associated with recurrence of tumor [156]. ECM1 is a potential plasma protein biomarker for the detection and progression of primary ESCC [157]. It is an unfavorable prognostic marker in renal cancer, urothelial cancer, and PDAC [36].…”

Section: Extracellular Matrix Protein I (Ecm1_human)mentioning

confidence: 99%

Construction of 2DE-Patterns of Plasma Proteins: Aspect of Potential Tumor Markers

Naryzhny¹,

Ронжина²,

Zorina³

et al. 2022

Preprint

View full text Add to dashboard Cite

Cancer is a complex systemic disease that changes the entire proteome. The analysis of this transformation makes it possible to determine tumor markers, that is, the most characteristic biomacromolecules produced by tumor cells. Here, the question of finding ideal tumor markers, which should be sensitive, specific, and reliable, is an acute issue. Unfortunately, none of the tumor markers, even those used in the clinic, has all these characteristics. Despite this, many tumor markers have demonstrated excellent clinical relevance for monitoring the effectiveness of different treatments for cancer patients. The use of markers also aids in the early detection of cancer recurrence and prognosis. Therefore, the situation in this area can be improved in two ways – by attempting to find an ideal single tumor marker or generating panels of different markers. In both cases, proteomics certainly plays a major role. Human plasma is one of the most popular samples as it is commonly collected in the clinic and provides noninvasive, rapid analysis for any type of disease including cancer. Many efforts have been applied in searching for “ideal” tumor markers digging very deep plasma proteome. There is a line of evidence that the most abundant, so-called “classical plasma proteins”, may be used to generate a tumor biomarker profile. To be comprehensive these profiles should have information not only about protein levels but proteoform distribution for each protein. Initially, the profile of these proteins in norm should be generated. Here, we present data about these profiles generated by two-dimensional electrophoresis with the following mass-spectrometry and immunodetection.

show abstract

“…Strong positive lumican immunostaining was found in the stromal and epithelial compartments of ESCC specimens but was almost negative in normal epithelium[ 103 ]. The concentration of lumican in plasma was identified as a potential biomarker of ESCC via a proteomic screen[ 104 ]. Nevertheless, a previous study by our group comparing a highly invasive ESCC subline with its parental cells showed that LUM decreased 8-fold in the highly invasive subline and was accompanied by activation of AKT pathway[ 105 ].…”

Section: Extracellular Proteoglycans In Esccmentioning

confidence: 99%

Proteoglycans and their functions in esophageal squamous cell carcinoma

Zhu¹,

Cheung²

2021

WJCO

View full text Add to dashboard Cite

Esophageal squamous cell carcinoma (ESCC) is a highly malignant disease that has a poor prognosis. Its high lethality is mainly due to the lack of symptoms at early stages, which culminates in diagnosis at a late stage when the tumor has already metastasized. Unfortunately, the common cancer biomarkers have low sensitivity and specificity in esophageal cancer. Therefore, a better understanding of the molecular mechanisms underlying ESCC progression is needed to identify novel diagnostic markers and therapeutic targets for intervention. The invasion of cancer cells into the surrounding tissue is a crucial step for metastasis. During metastasis, tumor cells can interact with extracellular components and secrete proteolytic enzymes to remodel the surrounding tumor microenvironment. Proteoglycans are one of the major components of extracellular matrix. They are involved in multiple processes of cancer cell invasion and metastasis by interacting with soluble bioactive molecules, surrounding matrix, cell surface receptors, and enzymes. Apart from having diverse functions in tumor cells and their surrounding microenvironment, proteoglycans also have diagnostic and prognostic significance in cancer patients. However, the functional significance and underlying mechanisms of proteoglycans in ESCC are not well understood. This review summarizes the proteoglycans that have been studied in ESCC in order to provide a comprehensive view of the role of proteoglycans in the progression of this cancer type. A long term goal would be to exploit these molecules to provide new strategies for therapeutic intervention.

show abstract

Identification of extracellular matrix protein 1 as a potential plasma biomarker of ESCC by proteomic analysis using iTRAQ and 2D‐LC‐MS/MS

Abstract: This proteome analysis indicate that ECM1 is a potential novel plasma protein biomarker for the detection of primary ESCC and evaluation of neoplasms progression.

Cited by 22 publications

References 68 publications

<p>Extracellular matrix protein 1 (ECM1) is associated with carcinogenesis potential of human bladder cancer</p>

<p>Extracellular matrix protein 1 (ECM1) is associated with carcinogenesis potential of human bladder cancer</p>

Construction of 2DE-Patterns of Plasma Proteins: Aspect of Potential Tumor Markers

Proteoglycans and their functions in esophageal squamous cell carcinoma

Contact Info

Product

Resources

About